ReviewMolecules (Basel, Switzerland)2023
MOF-Based Biosensors for the Detection of Carcinoembryonic Antigen: A Concise Review.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Stimuli-Responsive Intelligent Coatings With Nano/Microcarriers for Early Corrosion Sensing: Advances and Challenges.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Application of Metal-Organic Framework-Based Electrochemiluminescence Sensors for Mycotoxin Detection in Food.Biosensors · 2026Review
- Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026Review
- The sensitive and selective electrochemical detection of carcinoembryonic antigen using a nanoMIPs-aptamer sandwich assay.Scientific reports · 2025Article
- Metal-Organic-Framework-Based Optical Biosensors: Recent Advances in Pathogen Detection and Environmental Monitoring.Sensors (Basel, Switzerland) · 2025Review
- Design of a Zn-based porphyrin MOF biosensor for fluorometric detection of HER2 as a breast cancer biomarker.RSC advances · 2025Article
- Advances in carcinoembryonic antigen detection: a review of clinical applications and standardization.Analytical and bioanalytical chemistry · 2025Review
- Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer.Biosensors · 2025Review
- A Dual Nano-Signal Probe-Based Electrochemical Immunosensor for the Simultaneous Detection of Two Biomarkers in Gastric Cancer.Biosensors · 2025Article
- Biomedical Applications of Metal-Organic Frameworks Revisited.Industrial & engineering chemistry research · 2025Review
- Impedimetric Biosensors for the Quantification of Serum Biomarkers for Early Detection of Lung Cancer.Biosensors · 2024Article
- Cancer treatment approaches within the frame of hyperthermia, drug delivery systems, and biosensors: concepts and future potentials.RSC advances · 2024Review
- Colorimetric Immunoassays with Boronic Acid-Decorated, Peroxidase-like Metal-Organic Frameworks as the Carriers of Antibodies and Enzymes.Molecules (Basel, Switzerland) · 2024Article
- Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.International journal of molecular sciences · 2024Review
- An Overview of Electrochemical Sensors Based on Transition Metal Carbides and Oxides: Synthesis and Applications.Micromachines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has been considered one of the most serious diseases in recent decades. Early diagnosis of cancer is a crucial step for expedited treatment. Ideally, detection of cancer biomarkers, which are usually elevated because of cancer, is the most straightforward approach to detecting cancer. Among these biomarkers, the carcinoembryonic antigen (CEA) is considered one of the most important tumor markers for colorectal cancer. The CEA has also been recognized as a biomarker for other types of cancers, including breast, gastric, ovarian, pancreatic, and lung cancers. Typically, conventional CEA testing depends on immunoassay approaches, which are known to be complex, highly expensive, and time consuming. Accordingly, various types of biosensors have been designed for the detection of cancer biomarkers. The main prerequisites of these biosensors are high sensitivity, fast response, and low cost. Many nanostructures have been involved in the design of biosensors, such as nanoparticles of certain metals and metal oxides that are further functionalized to contribute to the sensing of the biomarkers. Alternatively, metal organic frameworks (MOFs), which are extended crystalline structures comprising metal clusters surrounded by organic linkers, have been shown to be highly promising for the development of biosensors. The 3D structure of MOFs results in a combination of high surface area and high interconnected porosity, which are believed to facilitate their function in the design of a biosensor. This review briefly classifies and describes MOF-based biosensor trials that have been published recently for the aim of detecting CEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.